Treatment with ORIC-101 reduced tumor levels of phospho-EGFR and cyclin D1 (Supplementary Fig. S3F) and suppressed tumor growth in a dose-dependent manner, with 150 mg/kg resulting in a median growth inhibition of 50% (Fig. 4H). The gene discussed is EGFR; the disease is neoplasm.